DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2244443/tela-bio-inc-tela-reports-q4-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2244443 Mar 21, 2024 - TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock? 0

https://www.zacks.com/stock/news/2244747/adicet-bio-acet-loses-16-39-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-ZC-FT-tale_of_the_tape|rsi-2244747 Mar 22, 2024 - The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. 0

https://www.zacks.com/stock/news/2246872/what-makes-instil-bio-til-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246872 Mar 27, 2024 - Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. 0

https://www.zacks.com/stock/news/2248367/is-adicet-bio-acet-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2248367 Apr 01, 2024 - Here is how Adicet Bio, Inc. (ACET) and Adma Biologics (ADMA) have performed compared to their sector so far this year. 0

https://www.zacks.com/stock/news/2251973/wall-street-analysts-see-a-218-92-upside-in-annovis-bio-anvs-can-the-stock-really-move-this-high?cid=CS-ZC-FT-tale_of_the_tape|consensus_price_target-2251973 Apr 08, 2024 - The average of price targets set by Wall Street analysts indicates a potential upside of 218.9% in Annovis Bio (ANVS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. 0

https://www.zacks.com/stock/news/2254517/is-entera-bio-entx-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2254517 Apr 12, 2024 - Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year. 0

https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012 Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs. 0

https://www.zacks.com/stock/news/2257849/bio-rad-laboratories-bio-to-post-q1-earnings-what-awaits?cid=CS-ZC-FT-analyst_blog|earnings_preview-2257849 Apr 18, 2024 - The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth. 0

https://www.zacks.com/stock/news/2258103/why-the-market-dipped-but-entera-bio-ltd-entx-gained-today?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2258103 Apr 18, 2024 - In the closing of the recent trading day, Entera Bio Ltd. (ENTX) stood at $2.24, denoting a +0.9% change from the preceding trading day. 0

https://www.zacks.com/stock/news/2273666/zura-bio-limited-zura-upgraded-to-buy-here-s-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2273666 May 14, 2024 - Zura Bio Limited (ZURA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). 0